A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma (AB-218-IIT-201)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05577416|
Recruitment Status : Recruiting
First Posted : October 13, 2022
Last Update Posted : October 13, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Glioma||Procedure: Biopsy Drug: Part A: AB-218 Procedure: Surgery (maximal resection) Drug: Part B: AB-218||Early Phase 1|
This is a single arm, open label Phase 0 trial to assess the feasibility, pharmacokinetics and pharmacodynamics of treatment with AB-218 following biopsy and prior to resection in patients with IDH1 mutated glioma.
Participants will receive treatment in 2 parts:
Part A: Biopsy followed by 1 cycle (28 days) of AB-218, an orally available, small molecular inhibitor of mutated IDH1, then safe maximal resection of the tumour.
Part B: Following recovery from surgery, patients will receive up to 12 cycles of AB-218.
It is expected that 10 patients will take part in this study.
It is anticipated this research study will enable investigators to objectively measure the biological activity of AB-218 in patients with IDH1 mutated LGG.
Anti-tumour activity will be assessed by RANO response criteria.
The investigators have previous experience in pre-treating patients with GBM prior to surgery with systemic therapies and collecting tumour, peri-tumour and normal brain tissues for PK, PD and biomarker evaluation
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Phase 0 'window of opportunity'/perioperative (Part A) followed by Phase 2 adjuvant treatment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 0/2 Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma|
|Actual Study Start Date :||October 11, 2022|
|Estimated Primary Completion Date :||December 1, 2024|
|Estimated Study Completion Date :||December 1, 2025|
Part A: Peri-operative treatment (Phase 0); Part B: Post operative adjuvant therapy (phase 2)
Patients will undergo stereotactic biopsy by craniotomy or burr hole.
Drug: Part A: AB-218
Part A: AB-218 orally 250 mg BID for 28 days.
Procedure: Surgery (maximal resection)
Surgery: Maximal safe resection, within 24 hours of last dose of AB-218.
Drug: Part B: AB-218
Part B: AB-218 orally 250 mg BID for 28 days for up to 12 cycles.
- Phase 0: Feasibility of Phase 0 study in patient population [ Time Frame: 14 months ]Number of patients to complete all planned investigations and procedures
- Phase 0: pharmacokinetic analysis of tumour tissue [ Time Frame: 4 weeks ]Total and unbound AB-218 in tumour tissue
- Phase 0: pharmacokinetic analysis of cerebrospinal fluid (CSF) [ Time Frame: 4 weeks ]Total and unbound AB-218 in CSF
- Phase 2: Number of Adverse events [ Time Frame: up to 30 days after last study dose ]Number of adverse events (AEs) according to NCI CTCAE v 5
- Phase 2: Incidence of drug related adverse events [ Time Frame: up to 30 days after last study dose ]Drug related adverse events
- Phase 2: Incidence of dose limiting toxicity [ Time Frame: up to 30 days after last study dose ]Dose limiting toxicity events
- Phase 0: Incidence of treatment emergent Adverse events [ Time Frame: during 1 cycle of AB-128, prior to maximal resection (4 weeks) ]Treatment emergent adverse events (AEs) according to NCI CTCAE v 5
- Phase 0: Safety of planned craniotomy and resection after stereotactic biopsy and treatment with AB-218 [ Time Frame: 30 days after maximal resection ]30-day morbidity and mortality post surgery
- Phase 0: Pharmacodynamic (PD) analysis of AB-218 in tumour [ Time Frame: after maximal resection (4 weeks), at progression (optional) ]Changes in 2-hydroxyglutarate (2-HG) levels in tumour
- Phase 0: Pharmacodynamic (PD) analysis of AB-218 in cerebrospinal fluid (CSF) [ Time Frame: after maximal resection (4 weeks), at progression (optional) ]Changes in 2-hydroxyglutarate (2-HG) levels in cerebrospinal fluid (CSF)
- Phase 0: Pharmacodynamic (PD) analysis of AB-218 in plasma [ Time Frame: after maximal resection (4 weeks), monthly during treatment, at progression (optional) ]Changes in 2-hydroxyglutarate (2-HG) levels in plasma
- Phase 0: anti-tumour activity [ Time Frame: 4 weeks ]Objective response (LGG RANO assessment)
- Phase 2: anti-tumour activity [ Time Frame: 8 weekly until progression ]Objective response (LGG RANO assessment)
- Phase 2: Survival [ Time Frame: 30 days after last study dose ]Progression free survival (PFS)
- Phase 2: Survival [ Time Frame: 30 days after last study dose ]Overall survival (OS)
- Phase 2: Survival [ Time Frame: 30 days after last study dose ]Time to treatment failure (TTF)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 40 Years (Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patients will have a radiological diagnosis of LGG or a previously confirmed LGG and be planned for elective, non-urgent resection of the tumour
- Patients who do not require urgent resection for mass effect, cerebral oedema or hydrocephalus in the opinion of the treating neurosurgeon
- Tumour size 2 - 5 cm
- Measurable and/or evaluable disease as per LGG-RANO criteria
- Willing to undergo planned surgical procedures
Routine trial inclusion criteria
- Adults ≥ 18 < 40 years of age
- ECOG performance score 0 - 1
- Life expectancy of at least 24 months
- Haematological and renal function as prescribed
- Hepatic function with prescribed limits
- Reproductive and contraception criteria as prescribed
Patients who meet any of the following criteria will be excluded from participation in the study:
- Patients who require urgent resection due to degree of mass effect, oedema, hydrocephalus or symptoms
- Patients who have received chemotherapy or radiation for the diagnosis of LGG
- Tumour involves cerebellum or brainstem
Routine trial exclusion criteria
- Any significant Intracranial bleeding in the opinion of the principal investigator
- Prior malignancy
- Significant co-morbidity
- ECG abnormalities
- Recent surgery
- Known allergy or sensitivity to any of the excipients in the investigational product
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05577416
|Contact: Kate Drummond, Prof||+61 3 9345 2767||AnHeart@wehi.edu.au|
|Royal Melbourne Hospital||Recruiting|
|Melbourne, Victoria, Australia|
|Contact: Kate Drummond|
|Principal Investigator:||Kate Drummond, Prof||Melbourne Health|
|Responsible Party:||Melbourne Health|
|Other Study ID Numbers:||
|First Posted:||October 13, 2022 Key Record Dates|
|Last Update Posted:||October 13, 2022|
|Last Verified:||October 2022|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue